Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. TVTX
TVTX logo

TVTX

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

TVTX News

Travere Therapeutics Secures FDA Approval for Filspari

22h agoYahoo Finance

Travere Therapeutics Director Sells Shares Amid FDA Approval

3h agoFool

US Stocks Surge as Oil Prices Plunge Amid Ceasefire Talks

5d agoNASDAQ.COM

Travere Therapeutics Grants Equity Inducements to New Employees

6d agoNewsfilter

US Stocks Rally as Oil Prices Plunge

6d agoNASDAQ.COM

US Stocks Rise on Hopes of Iran Ceasefire Negotiations

6d agoNASDAQ.COM

FDA Approves Filspari for Rare Kidney Disorder Treatment

6d agostocktwits

FDA Approves Travere and Ligand's Joint Kidney Disease Therapy Expansion

6d agoseekingalpha

FILSPARI Receives FDA Approval for FSGS Treatment

6d agoNewsfilter

Travere Therapeutics Receives FDA Approval for FILSPARI to Treat FSGS

6d agoNASDAQ.COM

Travere Therapeutics Receives FDA Approval for New Drug

6d agostocktwits

FDA Approves FILSPARI for FSGS Treatment

Apr 13 2026Newsfilter

FDA Extends Review Period for Filspari Drug Application

Apr 10 2026stocktwits

FDA Accelerates Biosimilar Drug Development and Approves New Treatments

Mar 30 2026NASDAQ.COM

Travere Therapeutics Q4 2025 Earnings Call Highlights

Feb 20 2026seekingalpha

Travere Therapeutics Reports Q4 Profit Exceeding Expectations

Feb 19 2026Yahoo Finance